The Biotech Boom: Bristol Myers Squibb's AI Deal Is More Than Meets the Eye The recent partnership between Bristol Myers Squibb (BMY) and Anthropic has sent shockwaves through the pharmaceutical industry, with investors taking notice of the potential upside catalyst.
This deal is more than just a clever public relations move – it's a strategic play that could revolutionize the way biotech companies approach innovation.
At its core, the partnership revolves around Anthropic's Claude AI model, which will be deployed across various functions within BMY.